Drugs / ART4215
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04991480 | Sep 2021 → Dec 2025 | breast cancer, metastatic malignant neoplasm | Artios Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART4215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04991480 ↗ |
| Action | Inhibit | “ART4215, a new first-in-class investigational medicinal product that is a potent and selective inhibitor of deoxyribonucleic acid (DNA) polymerase (pol) theta.” NCT04991480 ↗ |
| Route | Oral | “Participants will receive ART4215 by mouth daily in 21-day cycles.” NCT04991480 ↗ |